Superluminal Medicines
Latest round
- Series B
Last raised
- Aug 2026
Total raised
- $111M
Investors
- 13
About Superluminal Medicines
Based in Massachusetts, US, and founded in 2022 by co-founders Cony D'Cruz and Ajay Yekkirala, Superluminal Medicines Inc. develops drugs using biotechnology, generative biology, and chemistry. In September 2026, Superluminal Medicines Inc. Superluminal Medicines Inc. offers a platform that improves the process of drug candidate identification. The company use deep biology and chemistry expertise, machine learning algorithms, and proprietary big data infrastructure to generate candidate-ready compounds with unprecedented speed and precision. The platform's predict-design-test architecture, which utilises accurate protein shape modelling and the design of highly selective compounds, enables the targeting of precise structural changes to achieve therapeutic effects.
Who invested in Superluminal Medicines
13 investors across 3 rounds
See all investors in Superluminal Medicines
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Superluminal Medicines
Who invested in Superluminal Medicines?
Superluminal Medicines has 13 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Superluminal Medicines raised?
Superluminal Medicines has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Superluminal Medicines last raise money?
Superluminal Medicines's most recent round on record is a Series B, in Aug 2026.
What does Superluminal Medicines do?
Based in Massachusetts, US, and founded in 2022 by co-founders Cony D'Cruz and Ajay Yekkirala, Superluminal Medicines Inc.
Where is Superluminal Medicines headquartered?
Superluminal Medicines is headquartered in Boston, US.
Which VCs invest in companies like Superluminal Medicines?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Superluminal Medicines's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Superluminal Medicines? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.